Zimmer Biomet Holdings Inc on Tuesday beat Wall Street estimates for third-quarter profit, as a rebound in knee surgeries lifted demand for the medical device maker's products. On an adjusted basis, the company reported a profit of $1.65 per share, compared with analysts' average estimate of $1.60, according to LSEG data. Larger peers Abbott Laboratories and Boston Scientific had also topped quarterly profit estimates on easing staffing shortages and a surge in hospital admissions for elective procedures deferred during the pandemic.